# EDGAR Filing Document

**Accession Number:** 0002012593
**File Stem:** 0001193125-26-099377
**Filing Date:** 2026-3
**Character Count:** 15225
**Document Hash:** e9bec8e38ee7d67b25335e71fb216592
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-099377.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001193125-26-099377

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**EFFECTIVENESS DATE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rapport Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002012593
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880724208
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294169
- **FILM NUMBER:** 26737244

**BUSINESS ADDRESS:**
- **STREET 1:** 99 HIGH STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 857-321-8020

**MAIL ADDRESS:**
- **STREET 1:** 99 HIGH STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

**As filed with the Securities and Exchange Commission on March 10, 2026**

**Registration No. 333-**

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**FORM S-8<br>REGISTRATION STATEMENT<br> *UNDER***<br> ***THE SECURITIES ACT OF 1933***

**Rapport Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **88-0724208** |
| **(State or other jurisdiction of <br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| <br>**Rapport Therapeutics, Inc.**<br>**99 High Street, Suite 2100**<br>**Boston, MA** <br>**(Address of Principal Executive Offices)** | <br>**02110**<br>**(Zip Code)**<br>|

---

**Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan<br> (Full title of the plan)**

**Abraham N. Ceesay, M.B.A.<br> Chief Executive Officer<br> 99 High Street, Suite 2100**

**Boston, MA 02110**

**(Name and address of agent for service)**

**(857) 321-8020**

**(Telephone number, including area code, of agent for service)**

***Copies to:* <br> Kingsley L. Taft<br>Stephanie A. Richards**

**Goodwin Procter LLP<br>100 Northern Avenue<br>Boston, Massachusetts 02210<br>(617) 570-1000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**PART I<br> INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

This Registration Statement on Form S-8 (this "Registration Statement") is being filed by Rapport Therapeutics, Inc. (the "Registrant") for the purpose of registering 2,388,628 additional shares of common stock, par value $0.001 per share ("Common Stock"), under the Registrant's 2024 Stock Option and Incentive Plan (the "2024 Plan"), which were added on January 1, 2026 as a result of an automatic annual increase provision therein.

These additional shares are of the same class as other securities relating to the 2024 Plan for which the Registrant's registration statement on Form S-8, filed with the Securities and Exchange Commission on June 7, 2024 (File No. 333-280058) and March 11, 2025 (File No. 333-285697), are effective (the "Earlier Registration Statements").

Pursuant to General Instruction E to Form S-8 regarding registration of additional securities, the contents of the Earlier Registration Statements, except for "Item 8. Exhibits", are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Earlier Registration Statements are presented herein.

**PART II**<br> **INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8. Exhibits.**

The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 4.1 | [<u>Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-42121) filed on June 10, 2024).</u>](https://www.sec.gov/Archives/edgar/data/2012593/000119312524158327/d60139dex31.htm) |
| 4.2 | [<u>Form of Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-42121) filed on June 10, 2024).</u>](https://www.sec.gov/Archives/edgar/data/2012593/000119312524158327/d60139dex32.htm) |
| 4.3 | [<u>Amended and Restated Investors' Rights Agreement, by and between the Registrant and certain of its stockholders, dated as of August 7, 2023 (incorporated by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-279486), filed on May 17, 2024).</u>](https://www.sec.gov/Archives/edgar/data/2012593/000119312524141704/d803738dex42.htm) |
| 5.1\* | [<u>Opinion of Goodwin Procter LLP.</u>](rapp-ex5_1.htm) |
| 23.1\* | [<u>Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.</u>](rapp-ex23_1.htm) |
| 23.2\* | [<u>Consent of Goodwin Procter LLP (included in Exhibit 5.1).</u>](rapp-ex5_1.htm) |
| 24.1\* | Power of Attorney (included on signature page). |
| 99.1 | [<u>Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-279486) filed on June 3, 2024).</u>](https://www.sec.gov/Archives/edgar/data/2012593/000119312524152294/d803738dex102.htm) |
| 107\* | [<u>Filing Fee Table.</u>](rapp_exfilingfees.htm) |

---

------

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Massachusetts, on this 10<sup>th</sup> day of March, 2026.

---

| | |
|:---|:---|
| **RAPPORT THERAPEUTICS, INC.** | **RAPPORT THERAPEUTICS, INC.** |
| By: | /s/ Abraham N. Ceesay |
|  | Name: Abraham N. Ceesay, M.B.A. |
|  | Title: Chief Executive Officer |

---

 **POWER OF ATTORNEY AND SIGNATURES**

Each individual whose signature appears below hereby constitutes and appoints each of Abraham N. Ceesay, M.B.A. and Troy Ignelzi as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
|  **<u>Signature</u>**  |  **<u>Title</u>**  |  **<u>Date</u>**  |
| /s/ Abraham N. Ceesay | Chief Executive Officer and Director | March 10, 2026 |
| Abraham N. Ceesay, M.B.A. | (*Principal Executive Officer*) |  |
| /s/ Troy Ignelzi | Chief Financial Officer | March 10, 2026 |
| Troy Ignelzi | (*Principal Financial Officer and Principal Accounting Officer*) |  |
| /s/ Steven M. Paul | Director and Chairman | March 10, 2026 |
| Steven M. Paul, M.D. |  |  |
| /s/ James I. Healy | Director | March 10, 2026 |
| James I. Healy, M.D., Ph.D. |  |  |
| /s/ John Maraganore | Director | March 10, 2026 |
| John Maraganore, Ph.D. |  |  |
| /s/ Paul Silva | Director | March 10, 2026 |
| Paul Silva |  |  |
| /s/ Raymond Sanchez | Director | March 10, 2026 |
| Raymond Sanchez, M.D. |  |  |
| /s/ Robert J. Perez | Director | March 10, 2026 |
| Robert J. Perez |  |  |
| /s/ Reid Huber | Director | March 10, 2026 |
| Reid Huber, Ph.D. |  |  |
| /s/ Wendy B. Young | Director | March 10, 2026 |
| Wendy B. Young, Ph.D. |  |  |

---

------

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| <br>![img3483945_0.jpg](img3483945_0.jpg) | Goodwin Procter LLP<br>100 Northern Avenue<br>Boston, MA 02210<br>goodwinlaw.com<br>+1 617 570 1000 |

---

March 10, 2026

Rapport Therapeutics, Inc.

99 High Street, Suite 2100

Boston, Massachusetts 02110

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 2,388,628 shares (the "Shares") of Common Stock, par value $0.001 per share ("Common Stock"), of Rapport Therapeutics, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2024 Stock Option and Incentive Plan (the "Plan").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Goodwin Procter LLP

GOODWIN PROCTER LLP

------

## Exhibit 23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Rapport Therapeutics, Inc. of our report dated March 10, 2026 relating to the financial statements, which appears in Rapport Therapeutic's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP<br>Boston, Massachusetts<br>March 10, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107** 

**Calculation of** Filing Fee Table

**Form** S-8

(Form Type)

Rapport Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp; <br>Security Type | <br>**Security Class Title** | &nbsp;&nbsp;&nbsp; <br>**Fee Calculation Rule** | &nbsp;&nbsp;&nbsp; <br>**Maximum Aggregate Offering Price** | &nbsp;&nbsp;&nbsp; <br>**Fee Rate** | &nbsp;&nbsp;&nbsp; <br>**Amount of Registration Fee** |
| Equity | Common Stock, par value $0.001 per share | 457(h) and 457(c)<br> 2,388,628 shares<sup>(2)</sup><br>$27.60<sup>(3)</sup>  | $65926132.80 | 0.00013810 | $9104.40 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | $65926132.80 |  | $9104.40 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** |  |  | $9104.40 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's common stock , par value $0.001 per share ("Common Stock"), that become issuable under the Registrant's 2024 Stock Option and Incentive Plan (the "2024 Plan") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of Common Stock. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein.

(2) Represents an automatic increase to the number of shares of Common Stock available for issuance under the 2024 Plan, in accordance with the automatic annual increase provision therein, which was effective as of January 1, 2026. Shares available for issuance under the 2024 Plan were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission on June 7, 2024 (File No. 333-280058) and March 11, 2025 (File No. 333-285697).

(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, and based on the average of the high and low prices of the Common Stock reported on the Nasdaq Global Market on March 3, 2026.

------